DJIA 17,071.22 -41.93 -0.25%
NASDAQ 4,505.85 -6.34 -0.14%
S&P 500 1,977.80 -5.05 -0.25%
market minute promo

2.38 0.01 (0.42%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PLX $2.38 0.42%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.38
Previous Close $2.37
Daily Range $2.38 - $2.43
52-Week Range $2.35 - $5.30
Market Cap $222.9M
P/E Ratio 8.78
Dividend (Yield) $0.00 (0.0%)
Volume 271,229
Average Daily Volume 426,914
Current FY EPS -$0.15

Sector

Healthcare

Industry

Drugs

Protalix BioTherapeutics, Inc. (PLX) Description

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system. Website: http://www.protalix.com/

News & Commentary

3 High-Risk, High-Reward Biotech Stocks for Long Term Investors

Everyone wants to get rich, but investing in the wrong developmental companies can have disastrous consequences. Here are three companies with game-changing potential that have yet to hit their stride -- and may payoff in the long run.

How Protalix BioTherapeutics (PLX) Stock Stands Out in a Strong Industry - Tale of the Tape

How Protalix BioTherapeutics (PLX) Stock Stands Out in a Strong Industry - Tale of the Tape

Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog

Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Adds 8.3% in Session - Tale of the Tape

Sector Update: Health Care Stocks Mostly Lower; Regulators OK Expanded Use of Protalix Medication fo

Sector Update: Health Care Stocks Mostly Lower; Regulators OK Expanded Use of Protalix Medication for Gaucher Disease

Sector Update: Health Care

Why Protalix BioTherapeutics (PLX) Stock Is Surging Today

3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology

Stocks Hitting 52-Week Lows

Protalix Biotherapeutics Reports New Data on ELELYSO, Oral GCD Will Be Presented at European Working

Protalix Biotherapeutics Reports New Data on ELELYSO, Oral GCD Will Be Presented at European Working Group on Gaucher Disease

Protalix Drug in Phase IIa Study for Gaucher Disease - Analyst Blog

See More PLX News...

PLX's Top Competitors

PLX $2.38 (0.42%)
Current stock: PLX
AMGN $140.07 (-0.70%)
Current stock: AMGN
CELG $95.64 (1.25%)
Current stock: CELG
BIIB $330.16 (-1.01%)
Current stock: BIIB